Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule Impacts of the Restatement are Summarized Below (Details)

v3.26.1
Schedule Impacts of the Restatement are Summarized Below (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2025
Sep. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
ImpactsOfTheRevisionAreSummarizedBelowLineitem [Line Items]              
Research and development(1) $ 3,267,140 [1] $ 3,416,477 [1] $ 2,271,148 [1] $ 5,687,625 [1] $ 8,954,765 $ 17,220,401 $ 15,480,217 [2]
General and administrative(1) 466,926 [1] 352,838 [1] 497,602 [1] 850,440 [1] 1,317,366 2,227,517 2,157,010 [2]
Total operating expenses 3,734,066 3,769,315 2,768,750 6,538,065 10,272,131 19,447,918 17,637,227
Net loss $ (3,711,269) $ (3,748,640) $ (2,744,780) $ (6,493,420) $ (10,204,689) $ (19,358,218) $ (17,414,219)
Net loss per common share, basic $ (0.27) $ (0.28) $ (0.21) $ (0.49) $ (0.76) $ (1.43) $ (1.34)
Net loss per common share, diluted $ (0.27) $ (0.28) $ (0.21) $ (0.49) $ (0.76) $ (1.43) $ (1.34)
Net cash used in operating activities $ (1,834,454) $ (4,067,557) $ (6,738,796) $ (9,913,453) $ (7,266,543)
Liabilities 2,016,615 2,520,799 2,550,352 2,520,799 2,016,615 5,824,804 3,185,143
Liabilities and Equity 3,806,978 3,125,101 2,750,835 3,125,101 3,806,978 $ 6,178,021 4,093,769
Previously Reported [Member]              
ImpactsOfTheRevisionAreSummarizedBelowLineitem [Line Items]              
Research and development(1) 3,521,576 [1] 3,507,906 [1] 2,601,122 [1] 6,109,028 [1] 9,630,604   12,952,029 [2]
General and administrative(1) 653,066 [1] 538,047 [1] 681,210 [1] 1,219,257 [1] 1,872,323   3,059,788 [2]
Total operating expenses 4,174,642 4,045,953 3,282,332 7,328,285 11,502,927   16,011,817
Net loss $ (4,151,845) $ (4,025,278) $ (3,258,362) $ (7,283,640) $ (11,435,485)   $ (15,788,809)
Net loss per common share, basic $ (0.30) $ (0.30) $ (0.25) $ (0.55) $ (0.85)   $ (1.21)
Net loss per common share, diluted $ (0.30) $ (0.30) $ (0.25) $ (0.55) $ (0.85)   $ (1.21)
Net cash used in operating activities $ (1,834,454) $ (4,067,557) $ (6,738,796)   $ (7,266,543)
Liabilities 1,622,001 1,685,609 1,438,524 1,685,609 1,622,001   1,559,733
Liabilities and Equity 3,806,978 3,125,101 2,750,835 3,125,101 3,806,978   4,093,769
Revision of Prior Period, Reclassification, Adjustment [Member]              
ImpactsOfTheRevisionAreSummarizedBelowLineitem [Line Items]              
Research and development(1) (254,436) [1] (91,429) [1] (329,974) [1] (421,403) [1] (675,839)   2,528,188 [2]
General and administrative(1) (186,140) [1] (185,209) [1] (183,608) [1] (368,817) [1] (554,957)   (902,778) [2]
Total operating expenses (440,576) (276,638) (513,582) (790,220) (1,230,796)   1,625,410
Net loss $ 440,576 $ 276,638 $ 513,582 $ 790,220 $ 1,230,796   $ (1,625,410)
Net loss per common share, basic $ 0.03 $ 0.02 $ 0.04 $ 0.06 $ 0.09   $ (0.13)
Net loss per common share, diluted $ 0.03 $ 0.02 $ 0.04 $ 0.06 $ 0.09   $ (0.13)
Net cash used in operating activities      
Liabilities $ 394,614 $ 835,190 1,111,828 835,190 394,614   1,625,410
Liabilities and Equity  
[1] Includes reclassification of cash compensation and options expense between research and development and general and administration in 2025, which does not contribute to the change in total operating expenses for any period.
[2] Includes reclassification of cash compensation and options expense between research and development and general and administration in 2024, which does not contribute to the change in total operating expenses for any period.